Search results for " Polyethylene glycol"

showing 10 items of 40 documents

Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.

2005

Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoim…

MaleHepatitis C virusHepacivirusAcute hepatitis CAlpha interferonAutoimmunityHepacivirusInterferon alpha-2medicine.disease_causeIFNPolymyositisPolyethylene GlycolAntiviral AgentsVirusPolyethylene GlycolsPegylated interferonInterferonmedicineHumansDrug CarrierCreatine KinasePolymyositiAntiviral AgentDrug CarriersHepaciviruHepatologybiologybusiness.industryGastroenterologyInterferon-alphaHepatitis CRecombinant ProteinMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CRecombinant ProteinsAcute hepatitis C; Hepatitis C virus; IFN; Polymyositis; Acute Disease; Antiviral Agents; Autoimmunity; Creatine Kinase; Drug Carriers; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymyositis; RNA Viral; Recombinant Proteins; GastroenterologyPolymyositisImmunologyAcute DiseaseRNA ViralbusinessHepatitis C virumedicine.drugHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (E…

2015

Summary Background Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection. Methods Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that…

MalePhases of clinical researchHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundMedicinePharmacology (medical)ChronicAlisporivirAdolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young AdultGastroenterologyHepatitis CRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeCombinationCyclosporineDrug Therapy CombinationFemaleHumanUnited StateAdultmedicine.medical_specialtyAdolescentGenotypeAlpha interferonPlaceboAntiviral AgentsYoung AdultDrug TherapyDouble-Blind MethodInternal medicineRibavirinHumansAdverse effectAgedAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseUnited StatesRegimenchemistryImmunologybusinessAlimentary pharmacologytherapeutics
researchProduct

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

2013

International audience; Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT); and (3) BOC plus PegIFN/RBV for 44 weeks (BOC/PR48). The management of anemia (hemoglobin [Hb]<10 g/dL) included RBV dose reduction and/or erythropoietin (EPO) use. A total of 1,080…

Male[SDV]Life Sciences [q-bio]MedizinGastroenterologyPolyethylene GlycolsPlaceboschemistry.chemical_compoundHemoglobins0302 clinical medicinehemic and lymphatic diseasesMedicine030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaInterferon-alpha; Serine Proteinase Inhibitors; Proline; Recombinant Proteins; Hematinics; Humans; Ribavirin; Anemia; Antiviral Agents; Drug Therapy Combination; Erythropoietin; Hemoglobins; Adult; Treatment Outcome; Placebos; Polyethylene Glycols; Hepatitis C Chronic; Female; MaleAnemiaHepatitis CHepatitis CRecombinant Proteins3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeCombinationPeginterferon alfa-2b030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAnemiaInterferon alpha-2PlaceboAntiviral Agentsprotease inhibitor03 medical and health sciencesDrug TherapyInternal medicineBoceprevirRibavirinHumansAdverse effectErythropoietinHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgerychemistryErythropoietinHematinicsbusiness
researchProduct

Microscopic observations of superficial ultrastructure of unworn siloxane-hydrogel contact lenses by cryo-scanning electron microscopy

2006

The purpose of this study was to analyze three commercial siloxane-hydrogel contact lens materials, lotrafilcon A, balafilcon A, and galyfilcon A, by cryogenic scanning electron microscopy (cryoSEM). The fully hydrated lenses were frozen in slush liquid nitrogen and qualitatively observed in a cryogenic scanning electron microscope. The superficial ultrastructure of the siloxane-hydrogels was observed at the areas where the lens fractured during sample cryogenic preparation. There are qualitative differences among the three examined materials in the complex polymer network structure existing between the outer layer and the underlying polymer. CryoSEM, although destructive, is a useful tool …

Materials scienceSiloxanesScanning electron microscopeSurface PropertiesBiomedical Engineering02 engineering and technologyContact lens materialsHydrogel Polyethylene Glycol Dimethacrylatelaw.inventionBiomaterials03 medical and health sciences0302 clinical medicineOpticssilicone-hydrogellawMicroscopyMaterials TestingHumansCryo-scanning electron microscopyComposite materialchemistry.chemical_classificationScience & Technologybusiness.industryCryoelectron MicroscopyCryoSEM microscopyPolymerLiquid nitrogenpolymer surface021001 nanoscience & nanotechnologyContact Lenses HydrophilicSiloxane-hydrogel contact lensescryoSEMLens (optics)Contact lenschemistry030221 ophthalmology & optometryUltrastructuremicroscopysiloxane-hydrogels0210 nano-technologybusiness
researchProduct

Microscopic observation of unworn siloxane-hydrogel soft contact lenses by atomic force microscopy

2006

In the present study, samples of lotrafilcon A, balafilcon A, and galyfilcon A contact lenses were observed by atomic force microscopy (AFM) in tapping mode at areas ranging from 0.25 to 400 m2. Mean roughness (Ra), root-mean-square roughness (Rms) and maximum roughness (Rmax) in nanometers were obtained for the three lens materials at different magnifications. The three contact lenses showed significantly different surface topography. However, roughness values were dependent of the surface area to be analyzed. For a 1 m2 area, statistics revealed a significantly more irregular surface of balafilcon A (Ra = 6.44 nm; Rms = 8.30 nm; Rmax = 96.82 nm) compared with lotrafilcon A (Ra = 2.40 nm; …

Materials scienceSiloxanesSurface PropertiesBiomedical EngineeringNanotechnology02 engineering and technologyMicroscopy Atomic ForceHydrogel Polyethylene Glycol DimethacrylateBiomaterialsAtomic force microscopy03 medical and health scienceschemistry.chemical_compoundSurface roughness0302 clinical medicineMaterials TestingSurface roughnessHumansScience & TechnologyAtomic force microscopyContact Lenses Hydrophilic021001 nanoscience & nanotechnologySiloxane-hydrogel contact lenses3. Good healthMicroscopic observationchemistrySiloxaneWettability030221 ophthalmology & optometry0210 nano-technologyJournal of Biomedical Materials Research Part B: Applied Biomaterials
researchProduct

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial

2008

&lt;i&gt;Background:&lt;/i&gt; Based on the efficacy of pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer, we are conducting a phase III study comparing carboplatin plus either paclitaxel or PLD as first-line therapy in advanced ovarian cancer. Because of limited phase I and II data on PLD plus carboplatin in this setting, we conducted an interim activity analysis. &lt;i&gt;Patients and Methods:&lt;/i&gt; Patients with stage 1c-IV epithelial ovarian cancer were randomized to carboplatin AUC 5 plus either paclitaxel 175 mg/m&lt;sup&gt;2&lt;/sup&gt; or PLD 30 mg/m&lt;sup&gt;2&lt;/sup&gt; every 3 weeks for 6 cycles. The interim activity analysis was planned according to a single…

Oncologyarea under curveCancer Researchendocrine system diseasesmedicine.medical_treatmentneoplasmspolyethylene glycolsantibioticsPegylated Liposomal Doxorubicinsurvival analysischemistry.chemical_compoundpaclitaxelmiddle agedantineoplastic agentsNeoplasms Glandular and EpithelialhumansanthracyclinesAntibiotics AntineoplasticadultGeneral Medicineovarian neoplasmsfemale genital diseases and pregnancy complicationsagedovarian cancerfemaleOncologyPaclitaxelcarboplatinlipids (amino acids peptides and proteins)Anthracyclinesmedicine.drugmedicine.medical_specialtyantineoplasticantineoplastic combined chemotherapy protocolsglandular and epithelialdoxorubicinpegylated liposomal doxorubicinInternal medicineanthracyclines; carboplatin; ovarian cancer; paclitaxel; pegylated liposomal doxorubicin; adult; aged; antibiotics antineoplastic; antineoplastic agents; antineoplastic combined chemotherapy protocols; area under curve; carboplatin; doxorubicin; female; humans; middle aged; neoplasm staging; neoplasms glandular and epithelial; ovarian neoplasms; paclitaxel; polyethylene glycols; survival analysis; treatment outcomemedicineDoxorubicinneoplasm stagingAdvanced ovarian cancerChemotherapybusiness.industryCancermedicine.diseaseCarboplatinEndocrinologychemistrytreatment outcomebusinessOvarian cancer
researchProduct

Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…

2013

AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…

Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drug
researchProduct

Oxygen permeability of hydrogel contact lenses with organosilicon moieties

2002

Oxygen transport through two extended wear (day and night) hydrogel contact lenses that contain organosilicon moieties (balafilcon A and lotrafilcon A) was studied in the hydrate (hydrogel) and dry (xerogel) states. The water uptake increased the oxygen permeability [(Dk)app] and transmissibility [Dk/L(av)] coefficients of the dry materials by about 70%. The (Dk)app for the hydrated lenses was determined following the so-called stack procedure. The values obtained were 107 +/- 4 barrer for balafilcon A and 141 +/- 5 barrer for lotrafilcon A, about 5-10 times larger than those previously reported for conventional (without organosilicon moieties) extended wear hydrogels contact lenses. The Dk…

Optics and PhotonicsMaterials scienceBiophysicsAnalytical chemistrychemistry.chemical_elementBioengineeringOxygenHydrogel Polyethylene Glycol DimethacrylatePermeabilityBiomaterialschemistry.chemical_compoundOxygen permeabilityMaterials TestingPolymer chemistryOrganosilicon CompoundsOrganosiliconOxygen transportWaterContact Lenses HydrophilicOxygenchemistryMechanics of MaterialsPermeability (electromagnetism)Self-healing hydrogelsCeramics and CompositesBarrerHydrateBiomaterials
researchProduct